FUJIFILM Biosciences Bio-Expo Live November 2025: Upstream Bioprocessing

Scalable and cost-efficient production of viral vectors such as adeno-associated virus (AAV) and lentivirus (LV) is a critical challenge in the development of gene therapies. Traditional batch mode processes using HEK293 cells at low cell densities are limited by low productivity and high operational costs. In this study, we present a perfusion-based strategy using BalanCD HEK293 Perfusion A, a novel chemically defined medium optimized for suspension HEK293 cells, designed to boost cell growth and enhance vector yields while reducing production costs for efficient AAV and LV manufacturing.

Explore how:

• A novel chemically defined medium, combined with a tailored perfusion strategy, enables intensified processes while maintaining optimized control of nutrients and metabolites to support high cell density cultures for increased AAV and LV production
• Optimization of a perfusion ramping protocol can deliver cell-specific perfusion rate (CSPR) as low as 25 pL/cell/day for robust cell growth and increased productivity
• BalanCD HEK293 Perfusion A provides a versatile, scalable platform to meet the growing demands for high-titer viral vector production in the development of effective gene therapies